Journal article

Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer

Hui-Ming Lin, Kevin Huynh, Manish Kohli, Winston Tan, Arun A Azad, Nicole Yeung, Kate L Mahon, Blossom Mak, Peter D Sutherland, Andrew Shepherd, Natalie Mellett, Maria Docanto, Corey Giles, Margaret M Centenera, Lisa M Butler, Peter J Meikle, Lisa G Horvath

PROSTATE CANCER AND PROSTATIC DISEASES | SPRINGERNATURE | Published : 2021

Abstract

BACKGROUND: Dysregulated lipid metabolism is associated with more aggressive pathology and poorer prognosis in prostate cancer (PC). The primary aim of the study is to assess the relationship between the plasma lipidome and clinical outcomes in localised and metastatic PC. The secondary aim is to validate a prognostic circulating 3-lipid signature specific to metastatic castration-resistant PC (mCRPC). PATIENTS AND METHODS: Comprehensive lipidomic analysis was performed on pre-treatment plasma samples from men with localised PC (N = 389), metastatic hormone-sensitive PC (mHSPC)(N = 44), or mCRPC (validation cohort, N = 137). Clinical outcomes from our previously published mCRPC cohort (N = 1..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia


Awarded by Cancer Institute New South Wales


Awarded by Prostate Cancer Foundation of Australia


Awarded by Cancer Council New South Wales


Awarded by Cancer Council South Australia


Awarded by National Institutes of Health


Funding Acknowledgements

National Health and Medical Research Council of Australia (GNT0614296), Cancer Institute New South Wales (10/TPG/1-04, 2018/TPG001), Australian Prostate Cancer Research Centre-New South Wales, Australian Department of Health and Aging, the Movember Foundation and the Prostate Cancer Foundation of Australia (Revolutionary Team Award MRTA3), Cancer Council New South Wales (PG 10-01), Cancer Council South Australia (Beat Cancer Project Principal Cancer Research Fellowship, (PRF1117) to LMB), The Victorian Government's Operational Infrastructure Support Program, National Institutes of Health grant award to MK (RO1CA212097).